Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H19N3O3S |
Molecular Weight | 393.459 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=C(C=C1)C2=NN3N=CC=CC3=C2C4=CC=C(C=C4)S(C)(=O)=O
InChI
InChIKey=NXMZBNYLCVTRGB-UHFFFAOYSA-N
InChI=1S/C21H19N3O3S/c1-3-27-17-10-6-16(7-11-17)21-20(19-5-4-14-22-24(19)23-21)15-8-12-18(13-9-15)28(2,25)26/h4-14H,3H2,1-2H3
Molecular Formula | C21H19N3O3S |
Molecular Weight | 393.459 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/?term=19099009Curator's Comment: https://clinicaltrials.gov/ct2/show/NCT00279032?term=GW-406381&rank=1; https://clinicaltrials.gov/ct2/show/NCT00120900?term=GW-406381&rank=3; https://clinicaltrials.gov/ct2/show/NCT00113308?term=GW-406381&rank=4
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=19099009
Curator's Comment: https://clinicaltrials.gov/ct2/show/NCT00279032?term=GW-406381&rank=1; https://clinicaltrials.gov/ct2/show/NCT00120900?term=GW-406381&rank=3; https://clinicaltrials.gov/ct2/show/NCT00113308?term=GW-406381&rank=4
GW406381 is an investigational, highly selective cyclooxygenase-2 (COX-2) inhibitor for inflammatory pain treatment. It showed effectiveness in animal models of central sensitization such as chronic constriction injury and capsaicin-induced hyperalgesia. It's effect was also evaluated in several clinical trials in patients with peripheral nerve injury (Phase I ), rheumatoid arthritis (Phase III), the signs and symptoms of osteoarthritis of the knee to control of pain and improvement in function (Phase III), and in treating the signs and symptoms of dental pain following third molar tooth extraction (Phase III). Possessing favourable pharmacokinetic profiles and analgesic activity in vivo, GW406381 have also demonstrated relatively high brain penetration in the rat compared with the clinically available compounds, which may ultimately prove beneficial in the treatment of pain.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15454242
Curator's Comment: GW406381 demonstrated relatively high brain penetration in the rat compared with the clinically available compounds
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=27547824 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
700 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26331692 |
35 mg 1 times / day multiple, oral dose: 35 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GW-406381 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
70 mg single, oral Highest studied dose Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: Page: p.581 |
unhealthy, 22.2 n = 50 Health Status: unhealthy Condition: Pain Age Group: 22.2 Sex: M+F Population Size: 50 Sources: Page: p.581 |
|
50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 61.7 n = 109 Health Status: unhealthy Condition: Osteoarthritis of the Knee Age Group: 61.7 Sex: M+F Population Size: 109 Sources: |
Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | Disc. AE | 50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 61.7 n = 109 Health Status: unhealthy Condition: Osteoarthritis of the Knee Age Group: 61.7 Sex: M+F Population Size: 109 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. | 2004 Nov 1 |
|
The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. | 2005 Mar |
|
A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia. | 2009 Jun |
|
Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor. | 2016 May |
Sample Use Guides
5mg, 10mg, 25mg, and 50mg administered once daily for 12 weeks in adults with rheumatoid arthritis
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=27547824
Human whole blood stimulated with 100 ug/ml LPS was treated with GW406381. At 10 uM GW406381 profoundly reduced PGE2 and PGF2α (both by more than 90%, P < 0.0001), TxB2 (by more than 80%, P < 0.0001), and total 15-HETE (by more than 70%, P < 0.001)
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:41:24 GMT 2023
by
admin
on
Fri Dec 15 15:41:24 GMT 2023
|
Record UNII |
5Y869C2THE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60202043
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
DB12009
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
221148-46-5
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
5Y869C2THE
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
300000032859
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY | |||
|
9832687
Created by
admin on Fri Dec 15 15:41:24 GMT 2023 , Edited by admin on Fri Dec 15 15:41:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |